The Anticoagulant and Nonanticoagulant Properties of Heparin

被引:86
作者
Beurskens, Danielle M. H. [1 ]
Huckriede, Joram P. [1 ]
Schrijver, Roy [1 ]
Hemker, H. Coenraad [2 ]
Reutelingsperger, Chris P. [1 ]
Nicolaes, Gerry A. F. [1 ]
机构
[1] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Biochem, NL-6229 ER Maastricht, Netherlands
[2] Maastricht Univ, Cardiovasc Res Inst Maastricht, Synapse BV, Maastricht, Netherlands
关键词
heparin; anticoagulation; metastasis; inflammation; LOW-MOLECULAR-WEIGHT; FIBROBLAST-GROWTH-FACTOR; ACTIVATED PROTEIN-C; KAPPA-B ACTIVATION; CELL-ADHESION; P-SELECTIN; UNFRACTIONATED HEPARIN; ENDOTHELIAL-CELLS; PATHWAY INHIBITOR; ANTI-COAGULANT;
D O I
10.1055/s-0040-1715460
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparins represent one of the most frequently used pharmacotherapeutics. Discovered around 1926, routine clinical anticoagulant use of heparin was initiated only after the publication of several seminal papers in the early 1970s by the group of Kakkar. It was shown that heparin prevents venous thromboembolism and mortality from pulmonary embolism in patients after surgery. With the subsequent development of low-molecular-weight heparins and synthetic heparin derivatives, a family of related drugs was created that continues to prove its clinical value in thromboprophylaxis and in prevention of clotting in extracorporeal devices. Fundamental and applied research has revealed a complex pharmacodynamic profile of heparins that goes beyond its anticoagulant use. Recognition of the complex multifaceted beneficial effects of heparin underscores its therapeutic potential in various clinical situations. In this review we focus on the anticoagulant and nonanticoagulant activities of heparin and, where possible, discuss the underlying molecular mechanisms that explain the diversity of heparin's biological actions.
引用
收藏
页码:1371 / 1383
页数:13
相关论文
共 150 条
  • [1] Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation
    Achilles, A.
    Mohring, A.
    Dannenberg, L.
    Grandoch, M.
    Hohlfeld, T.
    Fischer, J. W.
    Levkau, B.
    Kelm, M.
    Zeus, T.
    Polzin, A.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (03) : 473 - 476
  • [2] Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro
    Adam, Albert
    Montpas, Nicolas
    Keire, David
    Desormeaux, Anik
    Brown, Nancy J.
    Marceau, Francois
    Westenberger, Benjamin
    [J]. BIOMATERIALS, 2010, 31 (22) : 5741 - 5748
  • [3] The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif -: the C-domain
    Al Dieri, R
    Wagenvoord, R
    Van Dedem, GWK
    Béguin, S
    Hemker, HC
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (05) : 907 - 914
  • [4] Aldea GS, 1996, ANN THORAC SURG, V62, P410, DOI 10.1016/0003-4975(96)00249-4
  • [5] Alonso DF, 1996, ONCOL REP, V3, P219
  • [6] Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models
    Alyahya, Reem
    Sudha, Thangirala
    Racz, Michael
    Stain, Steven C.
    Mousa, Shaker A.
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 46 (03) : 1225 - 1231
  • [7] The role of tissue factor pathway inhibitor in tumor growth and metastasis
    Amirkhosravi, Ali
    Meyer, Todd
    Amaya, Mildred
    Davila, Monica
    Mousa, Shaker A.
    Robson, Theresa
    Francis, John L.
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (07) : 643 - 652
  • [8] ANTICOAGULANT PROPERTIES OF HEPARIN FRACTIONATED BY AFFINITY CHROMATOGRAPHY ON MATRIX-BOUND ANTITHROMBIN-3 AND BY GEL-FILTRATION
    ANDERSSON, LO
    BARROWCLIFFE, TW
    HOLMER, E
    JOHNSON, EA
    SIMS, GEC
    [J]. THROMBOSIS RESEARCH, 1976, 9 (06) : 575 - 583
  • [9] INTERACTION OF HEPARIN WITH PLASMINOGEN ACTIVATORS AND PLASMINOGEN - EFFECTS ON THE ACTIVATION OF PLASMINOGEN
    ANDRADEGORDON, P
    STRICKLAND, S
    [J]. BIOCHEMISTRY, 1986, 25 (14) : 4033 - 4040
  • [10] Aznar J, 1996, THROMB HAEMOSTASIS, V76, P983